Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Brun

Showing results (331-340 of 385) with videos related to

Pageof 39
Sort By:
The Journal of Infectious Diseases|June 25, 2004
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patientsMartin S King, Barry M Bernstein, Sharon L Walmsley, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 17, 2007
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effectCheri Enders Klein, Yi-Lin Chiu, Walid Awni, et al.
Journal of Clinical Pharmacology|February 24, 2006
Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairmentJoanna Z Peng, Federico Pulido, Sonja J Kemmis Causemaker, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2008
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapySarah Palmer, Frank Maldarelli, Ann Wiegand, et al.
HIV Clinical Trials|August 28, 2007
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of responseDaniel Podzamczer, Martin S King, Cheri E Klein, et al.
Journal of Virology|July 20, 2001
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patientsD J Kempf, J D Isaacson, M S King, et al.
American Journal of Respiratory and Critical Care Medicine|May 1, 1996
Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolismB Godeau, A Schaeffer, D Bachir, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 27, 2015
COPD patients with ventilator-associated pneumonia: implications for managementD Koulenti, S Blot, J M Dulhunty, et al.
Proceedings. IEEE International Symposium on Biomedical Imaging|December 18, 2018
STATISTICALLY ASSISTED FLUID IMAGE REGISTRATION ALGORITHM - SAFIRACaroline C Brun, Natasha Lepore, Xavier Pennec, et al.
IEEE Transactions on Medical Imaging|September 4, 2010
A nonconservative Lagrangian framework for statistical fluid registration-SAFIRACaroline C Brun, Natasha Lepore, Xavier Pennec, et al.
Pageof 39

Showing results (331-340 of 385) with videos related to

Sort By:
Pageof 39
The Journal of Infectious Diseases|June 25, 2004
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patientsMartin S King, Barry M Bernstein, Sharon L Walmsley, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 17, 2007
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effectCheri Enders Klein, Yi-Lin Chiu, Walid Awni, et al.
Journal of Clinical Pharmacology|February 24, 2006
Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairmentJoanna Z Peng, Federico Pulido, Sonja J Kemmis Causemaker, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2008
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapySarah Palmer, Frank Maldarelli, Ann Wiegand, et al.
HIV Clinical Trials|August 28, 2007
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of responseDaniel Podzamczer, Martin S King, Cheri E Klein, et al.
Journal of Virology|July 20, 2001
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patientsD J Kempf, J D Isaacson, M S King, et al.
American Journal of Respiratory and Critical Care Medicine|May 1, 1996
Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolismB Godeau, A Schaeffer, D Bachir, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 27, 2015
COPD patients with ventilator-associated pneumonia: implications for managementD Koulenti, S Blot, J M Dulhunty, et al.
Proceedings. IEEE International Symposium on Biomedical Imaging|December 18, 2018
STATISTICALLY ASSISTED FLUID IMAGE REGISTRATION ALGORITHM - SAFIRACaroline C Brun, Natasha Lepore, Xavier Pennec, et al.
IEEE Transactions on Medical Imaging|September 4, 2010
A nonconservative Lagrangian framework for statistical fluid registration-SAFIRACaroline C Brun, Natasha Lepore, Xavier Pennec, et al.
Pageof 39